KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $2.30 $2.95 Friday, 26th Apr 2024 CLLS stock ended at $2.51. This is 0.627% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.62% from a day low at $2.35 to a day high of $2.51.
90 days $2.30 $3.13
52 weeks $0.96 $3.77

Historical Cellectis S.A. prices

Date Open High Low Close Volume
Apr 12, 2016 $27.70 $27.80 $27.16 $27.59 144 504
Apr 11, 2016 $28.83 $29.11 $27.85 $28.09 81 657
Apr 08, 2016 $29.61 $29.61 $28.62 $28.87 63 610
Apr 07, 2016 $30.02 $30.71 $28.73 $29.39 130 686
Apr 06, 2016 $28.89 $30.99 $28.89 $30.99 328 454
Apr 05, 2016 $27.84 $29.53 $27.84 $29.15 237 356
Apr 04, 2016 $27.71 $28.70 $27.71 $28.05 93 895
Apr 01, 2016 $27.11 $28.09 $27.01 $27.95 101 833
Mar 31, 2016 $27.03 $27.87 $26.95 $27.50 168 275
Mar 30, 2016 $27.05 $27.72 $26.89 $27.10 110 810
Mar 29, 2016 $26.55 $27.40 $26.55 $27.29 142 700
Mar 28, 2016 $27.59 $27.59 $26.58 $26.90 72 300
Mar 24, 2016 $26.72 $27.36 $26.65 $27.10 80 600
Mar 23, 2016 $27.43 $27.51 $26.86 $27.08 111 600
Mar 22, 2016 $27.03 $27.84 $27.03 $27.84 90 100
Mar 21, 2016 $27.09 $28.13 $26.95 $27.73 95 800
Mar 18, 2016 $26.00 $27.70 $25.88 $27.17 312 300
Mar 17, 2016 $25.01 $25.89 $24.90 $25.51 175 800
Mar 16, 2016 $24.86 $25.51 $24.70 $25.25 200 800
Mar 15, 2016 $25.86 $26.01 $24.74 $25.50 170 500
Mar 14, 2016 $25.00 $25.43 $24.67 $25.27 116 100
Mar 11, 2016 $25.20 $25.20 $24.68 $24.89 138 300
Mar 10, 2016 $25.03 $25.65 $24.25 $24.57 124 400
Mar 09, 2016 $25.75 $25.79 $24.39 $24.53 154 400
Mar 08, 2016 $26.48 $26.48 $25.15 $25.43 158 300
Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis S.A. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT